Skip to Main Content

Paper Details

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.
PLoS One
5
2021
AKT, CCNA2, CCNA2-H, CIP2A, Cancer, DNA sequences, E2F1, E2F1-H, EC, EC specimens, FBXW7, FBXW7-mu, FOXM1, GSK3, H, H TP53, POLE, PPP2R1A, TP53, TP53 mutant, TP53 wild type, TP53-mu, TP53-mu EC, TP53-mu and CCNA2-H TP53-wt EC, TP53-wt, TP53-wt EC, endometrial cancer, gene-specific RNA, mRNA, multiple homologous recombination genes, oncogenes, p21, p21 repressive sites, platinum, polymerase, promoter, promoter p21 repressive sites, protein phosphatase 2A
Author NameAffiliation
Mark E ShermanMayo Clinic
Mark E ShermanMayo Clinic
Saravut J WerohaMayo Clinic
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
  • 1 - 5

Datasets

Release 1.2